Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
ABBOTT PARK, Ill. - Abbott (NYSE: ABT), the $238 billion healthcare giant, announced today that its board of directors has declared a quarterly common dividend of 59 cents per share, representing a 1.73% yield, payable on Aug. 15, 2025, to shareholders of record as of July 15, 2025.
This marks Abbott’s 406th consecutive quarterly dividend since 1924. The healthcare company has increased its dividend payout for 53 consecutive years, maintaining its position in the S&P 500 Dividend Aristocrats Index, which includes companies that have raised dividends annually for at least 25 consecutive years.
Abbott, a global healthcare company, operates across multiple sectors including diagnostics, medical devices, nutritionals, and branded generic medicines. The company employs approximately 114,000 people and serves customers in more than 160 countries.
The dividend announcement was made in a press release statement issued by the company.
In other recent news, Abbott Laboratories has received approval from the U.S. Food and Drug Administration for its Tendyne transcatheter mitral valve replacement system. This approval expands Abbott’s portfolio in minimally invasive heart therapies and offers a new treatment option for patients with severe mitral annular calcification. Additionally, Abbott’s REFLECT studies revealed that its FreeStyle Libre continuous glucose monitoring technology significantly reduces hospitalizations due to heart complications in diabetes patients. The studies showed an 80% reduction in cardiovascular-related hospitalizations for Type 1 diabetes patients without prior cardiovascular disease.
In financial developments, Bernstein SocGen increased Abbott’s stock price target from $138 to $144, maintaining an Outperform rating. This adjustment follows an 8.3% organic sales growth, particularly in the Medical Devices segment. TD Cowen also raised Abbott’s stock price target to $145, citing a strong first-quarter performance with earnings per share of $1.09, surpassing EPS forecasts. RBC Capital Markets echoed this sentiment by increasing their price target to $145 and maintaining an Outperform rating, highlighting Abbott’s solid 8.3% year-over-year growth in its underlying business. These updates reflect confidence in Abbott’s financial resilience and strategic outlook amidst challenging market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.